     |
  |
|
|
Selecta Biosciences, Inc. is developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Selecta was founded based on the synergistic convergence of nanotechnology, targeted drug delivery and immunobiology by three pioneers in the field: Dr. Robert Langer of MIT, Dr. Omid Farokhzad and Dr. Ulrich von Andrian of Harvard Medical School.
